GLP-1/glucagon dual receptor agonist ALT-801 is superior to semaglutide in improving NASH endpoints in a biopsy-confirmed DIO mouse model

被引：0
|
作者：
Nestor, John [1 ]
Rigbolt, Kristoffer [2 ]
Feigh, Michael [2 ]
Parkes, David [3 ]
Harris, M. Scott [1 ]
机构：
[1] Altimmune Inc, Gaithersburg, MD USA
[2] Gubra, Horsholm, Denmark
[3] DGP Sci, Del Mar, CA USA
来源：
JOURNAL OF HEPATOLOGY | 2020年 / 73卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
FRI117
引用
收藏
页码：S456 / S456
页数：1
相关论文
共 45 条
  • [21] Potent weight loss mechanism and improvement of NASH by the long-acting GLP-1/glucagon receptor dual agonist HM12525A
    Jung, S.
    Lee, J.
    Kim, J.
    Lee, Y.
    Kim, Y.
    Kang, J.
    Trautmann, M.
    Hompesch, M.
    Kwon, S.
    DIABETOLOGIA, 2015, 58 : S380 - S380
  • [22] The GLP-1 analogue, liraglutide, reduces NAFLD Activity Score and Fibrosis Stage and improves metabolic parameters in a diet-induced obese mouse model of biopsy-confirmed nonalcoholic steatohepatitis (NASH)
    Tolbol, Kirstine S.
    Veidal, Sanne Skovgaard
    Knudsen, Sanne M.
    Erichsen, Helle K.
    Kristiansen, Maria N.
    Jelsing, Jacob
    Vrang, Niels
    Feigh, Michael
    HEPATOLOGY, 2016, 64 : 782A - 782A
  • [23] Detailed Analyses of the Antifibrotic effects of INT-767, a dual FXR/TGR5 agonist, in an obese mouse model of diet-induced and biopsy-confirmed NASH
    Veidal, Sanne Skovgaard
    Feigh, Michael
    Hansen, Henrik B.
    Jelsing, Jacob
    Vrang, Niels
    Petitjean, Matthieu
    Chen, Li
    Young, Mark
    Roth, Jonathan D.
    HEPATOLOGY, 2017, 66 : 1044A - 1044A
  • [24] COMBINATORY TREATMENT WITH MIR-22 ASO AND GLP-1 RA INCREASES POSITIVE OUTCOMES ON BODY WEIGHT AND LIVER PARAMETERS IN THE GAN DIET-INDUCED OBESE AND BIOPSY-CONFIRMED MOUSE MODEL OF NASH
    Panella, Riccardo
    Tomasini, Simone
    Feigh, Michael
    Kauppinen, Sakari
    HEPATOLOGY, 2023, 78 : S1194 - S1194
  • [25] The Dual GLP-1/GIP Receptor Agonist DA4-JC Shows Superior Protective Properties Compared to the GLP-1 Analogue Liraglutide in the APP/PS1 Mouse Model of Alzheimer's Disease
    Maskery, Mark
    Goulding, Elizabeth Mary
    Gengler, Simon
    Melchiorsen, Josefine Ulrikke
    Rosenkilde, Mette Marie
    Holscher, Christian
    AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS, 2020, 35
  • [26] Early clinical development of the dual GLP-1/glucagon receptor agonist SAR425899 and establishment of a population PK/PD model
    Lindauer, K.
    Goebel, B.
    Tillner, J.
    Posch, M.
    Teichert, L.
    Einig, C.
    Rimbault, M.
    Bergmann, K.
    Keil, S.
    Larsen, P. J.
    Lorenz, M.
    DIABETOLOGIA, 2016, 59 : S57 - S57
  • [27] MEDI0382, a dual GLP-1/glucagon receptor agonist, exerts beneficial effects on mitochondrial content and function in primary hepatocytes from lean and NASH mice
    Beaton, Michelle L.
    Grimsby, Joseph
    Rhodes, Christopher
    Jermutus, Lutz
    Konkar, Anish
    Trevaskis, James
    HEPATOLOGY, 2016, 64 : 787A - 787A
  • [28] Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimer's disease
    Tai, Jingjing
    Liu, Weizhen
    Li, Yanwei
    Li, Lin
    Holscher, Christian
    BRAIN RESEARCH, 2018, 1678 : 64 - 74
  • [29] MEDI0382, a GLP-1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomized, Phase 1 study
    Ambery, Philip D.
    Klammt, Sebastian
    Posch, Maximillian G.
    Petrone, Marcella
    Pu, Wenji
    Rondinone, Cristina
    Jermutus, Lutz
    Hirshberg, Boaz
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 84 (10) : 2325 - 2335
  • [30] A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson's disease by increasing expression of BNDF
    Ji, Chenhui
    Xue, Guo-Fang
    Cao Lijun
    Feng, Peng
    Li, Dongfang
    Li, Lin
    Li, Guanglai
    Hoelscher, Christian
    BRAIN RESEARCH, 2016, 1634 : 1 - 11
12345